Abstract
We report a case of a 65-year-old man with rheumatoid arthritis. The patient was treated with methotrexate and prednisolone, but the disease activity remained high. A tuberculin skin test was positive. After antituberculosis (TB) chemoprophylaxis with isoniazid for four weeks, infliximab was administered. Chemoprophylaxis was continued for nine months. Active lung TB was diagnosed at 17 months after the cessation of isoniazid, namely at 27 months after starting infliximab treatment. This case report shows that TB can manifest after chemoprophylaxis in patients treated with antitumor necrosis factor agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotorexate: a randomised phase III trial. Lancet. 1999;354:1932–9.
St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum. 2004;50:3432–43.
Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes LMW, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST Study). Arthritis Rheum. 2005;11:3381–90.
Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biological agents. Arthritis Rheum. 2005;52:3403–12.
Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–24.
Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune disease induced by TNF-targeted therapy. Medicine. 2007;86:242–51.
Geborek P, Bladström A, Turesson C. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Eng J Med. 2001;345:1098–104.
Furst DE, Wallis R, Broader M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36:159–67.
Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infections in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766–72.
Miyasaka N, Takeuchi T, Eguchi K. Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol. 2005;15:4–8.
Wolfe F, Michaud K, Urbansky K, Urbensky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50:372–9.
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum. 2003;48:2122–7.
Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847–50.
Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16:63–7.
British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60:800–5.
Mariette X, Salmon D, Group RATIO. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blocker. Ann Rheum Dis. 2003;62:791.
International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: 5 years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60:555–64.
Grant AD, Charalambous S, Fielding KL. Effects of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa. JAMA. 2005;293:2719–25.
Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006;10:1127–32.
Falagas ME, Voidonikola PT, Angelousi AG. Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents. 2007;30:477–86.
Madariaga MG, Lallo UG, Swindells S. Extensively drug-resistant tuberculosis. Am J Med. 2008;221:835–44.
Acknowledgments
This work was funded by the Aichi D.R.G. Foundation, Aichi, Japan.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hirano, Y., Kojima, T., Kanayama, Y. et al. A case of lung tuberculosis in a patient with rheumatoid arthritis treated with infliximab after antituberculosis chemoprophylaxis with isoniazid. Mod Rheumatol 19, 323–328 (2009). https://doi.org/10.1007/s10165-009-0157-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-009-0157-1